OncoHost

company

About

OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.

  • 1 - 10

Details

Last Funding Type
Series C
Last Funding Money Raised
$35M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners.

OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance.

OncoHost was founded in 2017 and is headquartered in Binyamina, Israel.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$43M
OncoHost has raised a total of $43M in funding over 2 rounds. Their latest funding was raised on May 10, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 10, 2022 Series C $35M 1 Detail
Jan 19, 2021 Series B $8M 1 OurCrowd Detail

Investors

Number of Lead Investors
Number of Investors
1
1
OncoHost is funded by 1 investors. OurCrowd are the most recent investors.
Investor Name Lead Investor Funding Round
OurCrowd Series C